



Substitute for form 1449A/PTO (Modified)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/631,106
				Filing Date	July 31, 2003
				First Named Inventor	BROWN, Dennis M.
				Art Unit	1614
				Examiner Name	To Be Assigned LESLIE A. ROYDS
Sheet	1	of	2	Attorney Docket Number	A-70245-2/RFT/THR (468899-00040)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LAR	A1 *	5,420,137	05-30-1995	Brana et al.	—
LAR	A2	6,734,178 B2	05-11-2004	Brown	—
LAR	A3	2003/0176496 A1	09-18-2003	Medford et al.	—

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
LAR	B1 *	FR 2 673 944 A1	09-18-1992	Elf Sanofi	—	—
LAR	B2 *	WO 01/68098 A2	09-20-2001	ChemGenex Therapeutics, Inc.	—	—

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T*
LAR	C1 *	ABBOTT, B.J., et al., "Screening Data from the Cancer Chemotherapy National Service Center Screening Laboratories. XXXVI. Plant Extracts," <i>Cancer Res. Supp.</i> , 26(9):1131-1136 (Sep. 1966).				
	C2 *	AJANI, J.A., et al., "In vitro activity of amonafide against primary human tumors compared with the activity of standard agents," <i>Invest. New Drugs</i> , 6(2):79-85 (Jun. 1988).				
	C3 *	ASBURY, R.F., et al., "A Gynecological Oncology Group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix," <i>Am. J. Clin. Oncol.</i> , 17(2):125-128 (Apr. 1994).				
	C4 *	BERNGES, F., et al., "Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines — with special reference to cisplatin," <i>J. Cancer Res. Clin. Oncol.</i> , 122(11):665-670 (1996).				
	C5 *	COBB, P.W., et al., "Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units," <i>J. Natl Cancer Inst.</i> , 86(19):1462-1465 (Oct. 1994).				
	C6 *	COSTANZA, M.E., et al., "Amonafide: An Active Agent in the Treatment of Previously Untreated Advanced Breast Cancer — A Cancer and Leukemia Group B Study (CALGB 8642)," <i>Clin. Cancer Res.</i> 1(7):699-704 (Jul. 1995).				
	C7 *	COSTANZA, M.E., et al., "Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study — Cancer and Leukemia Group B 8642," <i>J. Clin. Oncol.</i> , 17(5):1397-1406 (May 1999).				
	C8 *	EVANS, W.K., et al., "Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer," <i>J. Clin. Oncol.</i> , 8(3):390-395 (Mar. 1990).				
	C9 *	GALLION, H.H., et al., "Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study," <i>Gynecol. Oncol.</i> , 46(2):230-232 (Aug. 1992).				
LAR	C10 *	GÜNTHER, A., et al., "Differential Expression of Intermediate-Filament Proteins in Murine Sarcoma 180 Ascites or Solid Tumor," <i>Cancer Res.</i> , 44(6):2590-2594 (Jun. 1984).				
	C11 *	HAYES, D.F., et al., "Treatment of metastatic breast cancer: present and future prospects," <i>Semin. Oncol.</i> , 22(2 Suppl 5):6-19, disc 19-21 (Apr. 1995).				

Examiner Signature	Date Considered
	14-MARCH 2004

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO (Modified)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/631,106
				Filing Date	July 31, 2003
				First Named Inventor	BROWN, Dennis M.
				Art Unit	1614
				Examiner Name	To Be Assigned LESLIE A. RONDS
Sheet	2	of	2	Attorney Docket Number	A-70245-2/RFT/THR (468899-00040)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C12 *	INNOCENTI, F., "Pharmacogenetics: a tool for individualizing antineoplastic therapy," <i>Clin. Pharmacokinet.</i> , 39(5):315-325 (Nov. 2000).		
LAR	C13 *	JIN, X., et al., "Cisplatin combination therapy of murine S180," <i>Shanghai Yike Daxue Xuebao</i> , 16(1):50-54 (1989), Caplus Accession No. 1989:225174, (Abstract only).		
LAR	C14 *	LASTER, W.R., et al., "Therapeutic synergism (TS) of homoharringtonine (H) plus 5-fluorouracil (FU) against leukemia P388 (P388/0) and ARA-C-resistant P388 (P388/ARA-C)," <i>Proc. Am. Assn. Cancer Res.</i> , 23:786 (1982), Embase Accession No. 82182588, (Abstract only).		
LAR	C15 *	MAGNUSSON, K., et al., "Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?," <i>Oncogene</i> , 17(5):2333-2337 (Nov. 1998).		
	C16	MALONNE, H., et al., "DNA topoisomerase targeting drugs: Mechanisms of action and perspectives," <i>Anti-Cancer Drugs</i> , 8(9):811-822 (1997) (Abstract only).		
	C17 *	PÉREZ, J.M., et al., "Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis(naphthalimide) complexes," <i>J. Med. Chem.</i> , 42(26):5482-5486 (Dec. 1999).		
	C18	POWELL, R.G., "Antitumor alkaloids for <i>Cephalotaxus harringtonia</i> : structure and activity," <i>J. Pharm. Sci.</i> 61(8):1227-1230 (Aug. 1972).		
LAR	C19 *	PROVENCHER, D., et al., "Discordance in p53 Mutations When Comparing Ascites and Solid Tumors from Patients with Serous Ovarian Cancer," <i>Tumor Biol.</i> , 18(3):167-174 (1997).		
LAR	C20 *	SAVAGE, K.E., et al., "Effect of tunicamycin, an inhibitor of protein glycosylation, on division of tumour cells <i>in vitro</i> ," 64:295-306 (Nov. 1983).		
LAR	C21 *	TAKANO, I., et al., "Ester-type cephalotaxus alkaloids from <i>Cephalotaxus harringtonia</i> var. <i>drupacea</i> ," <i>Phytochemistry</i> , 44(4):735-738 (1997).		
LAR	C22 *	TAKANO, I., et al., "New Oxygenated <i>Cephalotaxus</i> Alkaloids from <i>Cephalotaxus harringtonia</i> var. <i>drupacea</i> ," <i>J. Nat. Prod.</i> , 59(12):1192-1195 (Dec. 1996).		
LAR	C23 *	VISANI, G., et al., "Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on <i>in vitro</i> growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors," <i>Leukemia</i> , 11:624-628 (May 1997).		
	C24 *	WONG, K., et al., "Management of metastatic breast cancer," <i>World J. Surg.</i> , 18(1):98-111 (Jan-Feb 1994).		
LAR	C25 *	YUZHU, Z., et al., "Homoharringtonine, cytarabine and aclarubicin (HAA) combination chemotherapy for acute myeloid leukemia (AML)," <i>Chin. J. Clin. Oncol.</i> , 25(10):758-759 (1998), Embase Accession No. 1998384948, (Abstract only).		
LAR	C26 *	ZHANG, S.D., et al., "Inhibitory effects of homoharringtonine and hydroxycamptothecin in combination with other agents on cancer cell growth," <i>Asia Pac. J. Pharmacol.</i> , 7:191-195 (1992).		

Examiner Signature		Date Considered	14 MARCH 2004
--------------------	---	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2